Phase 2a study shows improved vision with stem cell therapy for retinitis pigmentosa

VANCOUVER, British Columbia — Human retinal progenitor cell therapy from ReNeuron Group is showing positive preliminary results in the company’s ongoing phase 1/2a clinical trial involving patients with retinitis pigmentosa.
ReNeuron chief medical officer Richard Beckman, MD, told here at the Association for Research in Vision and Ophthalmology meeting that the three subjects in the current trial have shown subjective improvement in their visual acuity that has persisted for at least 2 months.
Study results were presented by researcher Jason Comander, MD, PhD, at the

Full Story →